Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 7/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884926 | 0.80 | FFAR1 (0.34) | FFAR1HMGCRVDRCYP24A1FFAR4 | |
| SCHEMBL2108294 | 0.78 | HMGCR (0.53) | HMGCRVDRCYP24A1LTB4R | |
| SCHEMBL2108296 | 0.78 | HMGCR (0.53) | HMGCRVDRCYP24A1LTB4R | |
| SCHEMBL16747415 | 0.78 | HMGCR (0.43) | FFAR1HMGCRVDRCYP24A1 | |
| SCHEMBL6155327 | 0.77 | HMGCR (0.54) | HMGCRVDRCYP24A1 | |
| SCHEMBL6155332 | 0.77 | HMGCR (0.54) | HMGCRVDRCYP24A1 | |
| SCHEMBL16747538 | 0.76 | HMGCR (0.44) | FFAR1HMGCRVDRCYP24A1 | |
| SCHEMBL7775051 | 0.74 | HMGCR (0.34) | FFAR1HMGCRVDRCYP24A1PTGES | |
| SCHEMBL2107016 | 0.74 | VDR (0.48) | FFAR1VDR | |
| SCHEMBL6155935 | 0.73 | IGF1R (0.41) | HMGCRVDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-2879656-B2 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2879649-B2 | DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT | OREAL (FR) | 2022-08-24 | — | — | EP | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-2879656-B1 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2019-05-29 | — | — | EP | disclosed |
| US-10226411-B2 | Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device | L'OREAL (FR) | 2019-03-12 | — | — | US | disclosed |
| US-10201483-B2 | Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device | L'OREAL (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-2879649-B1 | DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT | OREAL (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2018-08-23 | — | — | US | disclosed |
| US-20060233736-A1 | Cosmetic compositions containing mono-hydroxyl substituted amines and acid derivatives | L'OREAL (FR) | 2006-10-19 | — | — | US | disclosed |
| EP-1658838-A1 | Emulsification system for use in cosmetics | L'OREAL (FR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060039936-A1 | Emulsification system for use in cosmetics | L'OREAL (FR) | 2006-02-23 | — | — | US | disclosed |
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | L'OREAL (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1559398-A1 | Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins | L'OREAL (FR) | 2005-08-03 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226411-B2 | Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device | KRT18, OAT, DSG1 | FFAR1 1155/4885HMGCR 1759/4885VDR 3553/4885 |
| US-20060233736-A1 | Cosmetic compositions containing mono-hydroxyl substituted amines and acid derivatives | TYR, PHOSPHO1, DDC | FFAR1 1402/4885HMGCR 1495/4885VDR 1370/4885 |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | FFAR1 3676/4885HMGCR 283/4885VDR 4/4885 |
| US-10201483-B2 | Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device | KRT18, CUTA, DSG1 | FFAR1 272/4885HMGCR 844/4885VDR 3276/4885 |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | CUTA, DSG1, SUCLG1 | FFAR1 1727/4885HMGCR 565/4885VDR 4085/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | FFAR1 1727/4885HMGCR 565/4885VDR 4085/4885 |
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | KRT18, PROC, CUTA | FFAR1 4810/4885HMGCR 1113/4885VDR 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.